SIRPα interacts with CD47, a cell surface molecule often over-expressed on cancer cells. The CD47-SIRPα axis limits the antibody-mediated destruction of cancer cells through a ‘don’t eat me ...

which targeted the SIRPα receptor with which CD47 interacts. Last year, AbbVie also pulled out of a $1.3 billion R&D partnership with I-Mab on lemzoparlimab for MDS and AML, for undisclosed ...

Gilead is dealing with more turbulence in its development of CD47-targeting antibody magrolimab, with a partial clinical hold placed on the drug by the FDA in acute myeloid leukaemia (AML).

CD47 antibodies successfully blocked the binding of CD47 to its ligand signal regulatory protein α (SIRPα). In the BLI affinity assay, the affinity levels of these antibodies were equivalent to ...